<DOC>
	<DOC>NCT01621256</DOC>
	<brief_summary>The purpose of this study is to determine whether ancrod is effective and safe in the treatment of sudden sensorineural hearing loss (SSHL).</brief_summary>
	<brief_title>Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss</brief_title>
	<detailed_description />
	<mesh_term>Hearing Loss</mesh_term>
	<mesh_term>Deafness</mesh_term>
	<mesh_term>Ear Diseases</mesh_term>
	<mesh_term>Hearing Disorders</mesh_term>
	<mesh_term>Hearing Loss, Sensorineural</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ancrod</mesh_term>
	<criteria>Unilateral idiopathic sudden sensorineural hearing loss â‰¥30 dB Symmetric hearing prior to onset of SSHL Enrollment has to be accomplished within 7 days after SSHL onset Bilateral SSHL Incomplete recovery after previous SSHL Previously existing, known retrocochlear hearing loss Any history of any ear operation or local inflammatory disease in the past one year History of blunt or penetrating ear trauma, head trauma, barotrauma, or acoustic trauma immediately preceding SSHL History of Meniere's disease, autoimmune hearing loss, radiationinduced hearing loss, endolymphatic hydrops. Treatment with steroids for any reason within the preceding 30 days. Body weight &gt; 140 kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>